1Raman D,Sobolik-Delmaire T,Richmond A. Chemokines in health and disease[J].Experimental Cell Research,2011.575-589.
2Bonecchi R,Galliera E,Borroni EM. Chemokines and chemokine receptors:an overview[J].Frontiers in Bioscience,2009.540-551.
3White GE,Greaves DR. Fractalkine:A Survivor's Guide:Chemokines as Antiapoptotic Mediators[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2012.589-594.
4Graham GJ. D6 and the atypical chemokine receptor family:novel regulators of immune and inflammatory processes[J].European Journal of Immunology,2009.342-351.
5Fraticelli P,Sironi M,Bianchi G. Fractalkine (CX3CL1) as an amplifi cation circuit of polarized Th1 responses[J].Journal of Clinical Investigation,2001.1173-1181.
6Umehara H,Bollm ET,Okazaki T. Fractalkine and vascular injury[J].Trends in Immunology,2001.602-607.
7Maghazachi AA. Role of chemokines in the biology of natural killer cells[J].Current Topics in Microbiology and Immunology,2010.37-58.
8Robertson MJ. Role of chemokines in the biology of natural killer cells[J].Journal of Leukocyte Biology,2002.173-183.
9Gorini S,Callegari G,Romagnoli G. ATP secreted by endothelial cells blocks CX3CL 1-elicited natural killer cell chemotaxis and cytotoxicity via P2Y11 receptor activation[J].Blood,2010.4492-4500.
10Efsen E,Gralppone C,Defranco RM. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in human[J].Journal of Hepatology,2002.39-47.
